10-Q quarterly report · filed Nov 12, 2026

Altimmune, Inc. (ALT) Q3 2026 10-Q Quarterly Report

Short answer

Altimmune, Inc. (ALT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$32M
−66.2% YoY · −38.5% QoQ
EPS (diluted)
−$0.16
+23.8% YoY · −45.5% QoQ

Source: XBRL data from the Altimmune, Inc. (ALT) Q3 2026 10-Q on SEC EDGAR. USD.

Altimmune, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, down 100% YoY from $5,000
  • Net loss $31.6M vs $19.0M YoY, operating loss $35.7M vs $20.9M
  • Best-performing line: MASH R&D $10.7M, up $6.9M YoY; AUD R&D $1.9M, down $1.4M
  • Cash used in operations $82.9M, investments $451.0M at September 30, 2026
  • April offering raised $211.1M net; management expects funding for at least twelve months, with tariff and inflation risks ahead

Risk Factors

  • No material changes from the March 6, 2026 Form 10-K risk factors

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Altimmune, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.